Targanta Therapeutics Presents Preclinical In Vivo Data Demonstrating Activity of Oritavancin against Clostridium Difficile Infection

WASHINGTON--(BUSINESS WIRE)--Targanta Therapeutics Corporation (NASDAQ: TARG) today released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection. Results are being presented in a poster (B-067) today at 12:15 pm EDT entitled, “Efficacy of Oritavancin against Clostridium difficile (CD) infection in the Hamster Model of CD infection (CDI)” at the combined annual meetings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the 46th Infectious Disease Society of America (IDSA), taking place in Washington, DC.

Back to news